Monteplase
Monteplase was approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on March 14, 2008. It was developed and marketed as Cleactor® by Eisai.
Monteplase is a tissue plasminogen activator, which binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It is indicated for the treatment of patients with acute myocardial infarction and acute massive pulmonary embolism.
Cleactor® is available as injection (lyophilized powder) for intravenous use, containing 400000 IU, 800000 IU or 1200000 IU of Monteplase. The recommended dose is 27500 IU/kg for acute myocardial infarction, 13750-27500 IU/kg for acute massive pulmonary embolism.
General Information
Update Date：2015-10-30
- Drug Name：
- Monteplase
- Research Code：
- E-6010
- Trade Name：
- Cleactor®
- MOA：
- Catalyze the conversion of plasminogen to plasmin
- Indication：
- Acute myocardial infarction (AMI); Acute massive pulmonary embolism
- Status：
- Approved
- Company：
- Eisai (Originator)
- Sales：
- ATC Code：
Approved Countries or Area
Update Date：2015-09-07
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 2008-03-14 | Marketing approval | Cleactor | Acute myocardial infarction (AMI), Acute massive pulmonary embolism | Injection, Lyophilized powder, For solution | 400000 IU; 800000 IU; 1200000 IU | Eisai | Orphan |
Biology Structure
Update Date：2015-09-07
| Type | Recombinant enzyme |
|
| Source | Human | |
| Molecular Formula | C2569H3896N746O783S39; C2580H3916N752O786S39 | |
| Molecular Weight | ~68000 | |
| CAS No. | 105913-11-9 | |
| Expression System | Mammalian Cell |